(Q36960802)

English

Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.

scientific article published on June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. (English)

1 reference

Europe PubMed Central

17 August 2017

endometrial carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

object named as

Alexia Iasonos

1 reference

Europe PubMed Central

17 August 2017

1

object named as

Vicky Makker

1 reference

Europe PubMed Central

17 August 2017

Carol Aghajanian

5

object named as

Carol A Aghajanian

1 reference

Europe PubMed Central

17 August 2017

author name string

Martee L Hensley

2

1 reference

Europe PubMed Central

17 August 2017

Qin Zhou

3

1 reference

Europe PubMed Central

17 August 2017

publication date

1 June 2013

1 reference

Europe PubMed Central

17 August 2017

International Journal of Gynecological Cancer

1 reference

Europe PubMed Central

17 August 2017

23

1 reference

Europe PubMed Central

17 August 2017

5

1 reference

Europe PubMed Central

17 August 2017

929-934

1 reference

Europe PubMed Central

17 August 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Anthracyclines in the treatment of gynecologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

29 September 2017

Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

27 June 2018

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

4 September 2018

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

4 September 2018

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

4 September 2018

Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3694716

4 December 2018

Liposomal doxorubicin: a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23598889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/IGC.0B013E3182915C20

1 reference

Europe PubMed Central

17 August 2017

release_qjxsjnyalfgohhpfepk26yokpq

1 reference

https://api.fatcat.wiki/v0/release/qjxsjnyalfgohhpfepk26yokpq

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

0 references

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36960802&oldid=2047140140"